Pazopanib-induced organizing pneumonia in a patient with leiomyosarcoma: A case report

Pazopanib, a multityrosine kinase inhibitor used for treating malignant soft tissue tumors, rarely causes adverse events associated with the respiratory system. We report a case of a 73-year-old male with leiomyosarcoma treated with pazopanib. Four months after treatment initiation, chest computed t...

Descripción completa

Detalles Bibliográficos
Autores principales: Watanabe, Chie, Miyata, Jun, Esaki, Kotoba, Suematsu, Ryohei, Sano, Tomoya, Yamamoto, Takayuki, Sasaki, Hisashi, Maki, Yohei, Tagami, Yoichi, Kimizuka, Yoshifumi, Fujikura, Yuji, Ito, Keiichi, Kawana, Akihiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7276494/
https://www.ncbi.nlm.nih.gov/pubmed/32528844
http://dx.doi.org/10.1016/j.rmcr.2020.101112
Descripción
Sumario:Pazopanib, a multityrosine kinase inhibitor used for treating malignant soft tissue tumors, rarely causes adverse events associated with the respiratory system. We report a case of a 73-year-old male with leiomyosarcoma treated with pazopanib. Four months after treatment initiation, chest computed tomography showed bilateral patchy consolidation and ground-glass opacities. Bronchoscopy revealed increased lymphocytes in the bronchoalveolar lavage fluid. Histological analysis of lung tissue demonstrated intraluminal fibrotic changes in alveolar spaces. According to these findings, we diagnosed the patient with pazopanib-induced organizing pneumonia. To best of our knowledge, this is the first report of such a case.

Ejemplares similares